The Thesis
channel-pullback is a classic buy-the-dip strategy with discipline built in. It waits for a confirmed uptrend, then buys pullbacks into the lower regression channel or a volume-support zone, aiming to exit at the upper channel or overhead resistance. The universe is a conservative, liquid 24-name basket spanning mega-cap tech (AAPL, MSFT, NVDA), financials (JPM, V, MA), staples (PG, KO, WMT, COST) and healthcare (JNJ, UNH). This is a strategy designed to harvest short-term reversion inside longer-term trends — not to chase momentum breakouts.
Recent Activity
Activity over the past two weeks has been measured. Scheduled runs from 2026-07-29 through 2026-08-05 executed at most one trade per session, with several days flat. The paper account sits at roughly $10,035 total equity against a $10,000 base, with cash swinging between about $2,835 and $6,461 as positions cycle.
The trade tape tells the intended story. The book took profits on UNH (bought 420.31, sold 433.57) and PG (bought 145.99, sold 150.90), and rotated out of KO and CAT before re-entering CAT at 887.13 and adding AAPL and PG. These are small, quick round-trips consistent with a pullback-and-release approach rather than long-hold conviction.
Backtest Performance
Over 451 days the strategy returned 7.62% (CAGR 4.19%), ending at $10,761 in equity. The headline numbers are honest but modest: Sharpe of 0.40, a 14.83% max drawdown, and a 39.39% win rate across 137 trades. A sub-40% win rate that still nets a gain implies winners outrun losers — the exit-at-resistance rule appears to be doing real work. Turnover, however, is a striking 2,311%, meaning capital churns roughly 23x. At current scale fees are trivial ($137 total), but that churn would bite harder with slippage or on larger size.
Validation — The Red Flag
The walk-forward validation did not pass, and this is where balance matters. Three of four folds were positive, and Fold 3 (2025-07 to 2025-12) was excellent: +20.68% at a Sharpe of 3.86. But Fold 2 (2025-01 to 2025-07) lost 11.42% at a Sharpe of -1.70 — evidence the strategy can break badly when trends whipsaw. Out-of-sample return was a thin 3.63% (Sharpe 0.74), well below the full-sample figure.
Most telling are the robustness statistics. Across 7 trials, the Probabilistic Sharpe Ratio is a decent 0.702, but the Deflated Sharpe Ratio collapses to 0.196 once trial selection is penalized. In plain terms: after accounting for how many variants were tried, we cannot confidently reject the possibility that the edge is noise.
Verdict
channel-pullback is a coherent, low-cost strategy with a clean logic and genuine profit-taking behavior. But the negative fold and weak deflated Sharpe are real warnings — its returns lean heavily on favorable regimes. It earns continued paper-trading observation, not fresh capital, until it shows it can survive another Fold-2-style stretch.